GLP-1 medications reduced the risk of major adverse cardiovascular events by 13% compared to a placebo, according to a study published Nov. 25 in The Lancet Diabetes & Endocrinology.

In this randomized controlled trial, among patients with a history of myocardial infarction (MI), interruption of long-term beta-blocker therapy was not found to be noninferior to beta-blocker ...